- IBD
-
Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
-
Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein
-
Intest Res 2022;20(1):72-77. Published online February 3, 2021
-
DOI: https://doi.org/10.5217/ir.2020.00117
-
-
Abstract
PDF PubReader ePub
- Background/Aims
Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn’s disease (CD). However, even with earlier usage of biologic therapy, a significant proportion of patients will require surgery. Vedolizumab is an anti-integrin antibody that is increasingly used given that it is more gut selective and associated with fewer side effects. The aim of this study is to assess the effect of vedolizumab compared to anti-tumor necrosis factor (anti-TNF) therapy on the perioperative complications in patients undergoing surgery for inflammatory bowel disease (IBD).
Methods Retrospective review of patients treated for IBD at a tertiary care center between 2013 and 2017. Rates of 30- and 90-day complications for patients on vedolizumab were compared to patients on anti-TNF regimens.
Results One hundred and ninety-nine patients met inclusion criteria with 87 (43%) patients undergoing surgery for CD, 111 (55.8%) for UC and 1 (0.5%) for indeterminate colitis. Thirty-eight patients received preoperative vedolizumab and 94 received anti-TNF. There were more males and lower body mass index in the anti-TNF group. There was no significant difference in overall rate of complications at 30 or 90 days. There was a trend for lower leak rate vedolizumab group (0% for vedolizumab vs. 2.1% for anti-TNF at 30 days, P= 1.00; 0% for vedolizumab vs. 1.1% for anti-TNF at 90 days, P= 1.00). Multivariate analysis showed low albumin ( < 3.6 g/dL) at the time of surgery to be a significant risk factor for overall and infectious complications at 90 days (odds ratio, 3.24; 95% confidence interval, 1.12–8.79; P= 0.021).
Conclusions Perioperative vedolizumab does not increase rates of perioperative complications in IBD surgery when compared to anti-TNF medications.
-
Citations
Citations to this article as recorded by 
- Safety and Monitoring of Inflammatory Bowel Disease Advanced Therapies
Shubha Bhat, Benjamin Click, Miguel Regueiro Inflammatory Bowel Diseases.2024; 30(5): 829. CrossRef - Newer Immunosuppressants for Rheumatologic Disease
Ye Rin Koh, Kenneth C. Cummings Anesthesiology Clinics.2024; 42(1): 131. CrossRef - Peri-Operative Optimization of Patients with Crohn’s Disease
Hareem Syed, Ahmed Nadeem, David Gardinier, Kendra Weekley, Dovid Ribakow, Stephen Lupe, Shubha Bhat, Stefan Holubar, Benjamin L. Cohen Current Gastroenterology Reports.2024; 26(5): 125. CrossRef - Clinical Significance of Prognostic Nutrition Index in Patients with Crohn’s Disease after Primary Bowel Resection
Hyeon Woo Bae, Yong Joon Lee, Min Young Park, Seung Yoon Yang, Yoon Dae Han, Min Soo Cho, Hyuk Hur, Kang Young Lee, Jae Hee Cheon, Joseph C. Carmichael, Byung Soh Min Yonsei Medical Journal.2024; 65(7): 380. CrossRef - Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study
Gabriele Dragoni, Tommaso Innocenti, Aurelién Amiot, Fabiana Castiglione, Laura Melotti, Stefano Festa, Edoardo Vincenzo Savarino, Marie Truyens, Konstantinos Argyriou, Daniele Noviello, Tamas Molnar, Vincent Bouillon, Cristina Bezzio, Piotr Eder, Samuel American Journal of Gastroenterology.2024; 119(8): 1525. CrossRef - Newer Immunosuppressants for Rheumatologic Disease
Ye Rin Koh, Kenneth C. Cummings Rheumatic Disease Clinics of North America.2024; 50(3): 545. CrossRef - Full Guidelines—From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis
Warren A. James, Angela L. Rosenberg, Jashin J. Wu, Sylvia Hsu, April Armstrong, Elizabeth B. Wallace, Lara Wine Lee, Joseph Merola, Sergio Schwartzman, Dafna Gladman, Clive Liu, John Koo, Jason E. Hawkes, Soumya Reddy, Ron Prussick, Paul Yamauchi, Michae Journal of the American Academy of Dermatology.2024; 91(2): 251.e1. CrossRef - Tofacitinib Exposure Does Not Increase Postoperative Complications Among Patients With Ulcerative Colitis Undergoing Total Colectomy: A Retrospective Case–Control Study
Ibrahim Gomaa, Sara Aboelmaaty, Himani Bhatt, Robert A. Vierkant, Sherief F. Shawki, David W. Larson, Kevin T. Behm, Kristen K. Rumer Diseases of the Colon & Rectum.2024; 67(11): 1443. CrossRef - An update on the safety of long-term vedolizumab use in inflammatory bowel disease
Sailish Honap, Patrick Netter, Silvio Danese, Laurent Peyrin-Biroulet Expert Opinion on Drug Safety.2023; 22(9): 767. CrossRef - Perioperative Management of Pediatric Crohn’s Disease
Brad Pasternak, Ashish Patel, Paul Tran, Lisa McMahon Journal of Pediatric Gastroenterology & Nutrition.2023; 76(2): 137. CrossRef - Perioperative Assessment and Optimization in Major Colorectal Surgery: Medication Management
William J. Kane, Puja Shah Berry Clinics in Colon and Rectal Surgery.2023; 36(03): 210. CrossRef - Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?
Jihye Park Intestinal Research.2022; 20(1): 1. CrossRef - Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef - Anti -TNFα agents in preventing the postoperative recurrence of Crohn’s disease: Do they still play a role in the biological era?
Caiguang Liu, Na Li, Shukai Zhan, Zhenyi Tian, Dongxuan Wu, Tong Li, Zhirong Zeng, Xiaojun Zhuang Expert Opinion on Biological Therapy.2021; : 1. CrossRef
-
5,996
View
-
385
Download
-
12
Web of Science
-
14
Crossref
|